Cargando…

Evaluation of a novel very high sun-protection-factor moisturizer in adults with rosacea-prone sensitive skin

BACKGROUND/OBJECTIVE: Rosacea-prone sensitive skin requires high sun-protection factor (SPF) moisturizers. This study evaluated Daylong Extreme SPF 50+ lotion, a novel cream containing five ultraviolet filters, two emollients, and three skin conditioners. SUBJECTS AND METHODS: This was an open-label...

Descripción completa

Detalles Bibliográficos
Autores principales: Grivet-Seyve, Mathieu, Santoro, Francine, Lachmann, Nadège
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476437/
https://www.ncbi.nlm.nih.gov/pubmed/28652793
http://dx.doi.org/10.2147/CCID.S134857
_version_ 1783244599171481600
author Grivet-Seyve, Mathieu
Santoro, Francine
Lachmann, Nadège
author_facet Grivet-Seyve, Mathieu
Santoro, Francine
Lachmann, Nadège
author_sort Grivet-Seyve, Mathieu
collection PubMed
description BACKGROUND/OBJECTIVE: Rosacea-prone sensitive skin requires high sun-protection factor (SPF) moisturizers. This study evaluated Daylong Extreme SPF 50+ lotion, a novel cream containing five ultraviolet filters, two emollients, and three skin conditioners. SUBJECTS AND METHODS: This was an open-label, single-center study. On day 1, before treatment, subjects answered a questionnaire on their skin conditions and sunscreen habits, and both subjects and dermatologist evaluated skin status. Subjects applied the product once daily in the morning to the face for 21 days, and after approximately 3–5 minutes they assessed tolerability and short-term cosmetic acceptability in a questionnaire and daily diary. On day 22, the dermatologist and subjects evaluated skin status for long-term tolerance and cosmetic acceptability. RESULTS: The study enrolled 44 individuals (mean age 58.8 years, 91% female). At baseline, most subjects (39 of 44) showed erythema, and ~30% showed dryness and scaling. Dermatologists noted four cases of pustules and one case of papules. After 21 days’ treatment with the product, the dermatologist reported significantly less erythema, dryness and scaling, three cases of pustules and two cases of papules. At baseline, ~75% of subjects noted a feeling of dryness, >50% reported tension, and nearly 25% reported tickling. After using the product for 21 days, subjects reported significantly less tension, dryness, and tickling. Some subjects noted itching and burning before and after using the product. One subject noted papules during treatment. Most subjects said that the product was pleasant, did not irritate the skin or cause stinging/burning, was easy to apply, quickly absorbed, and nongreasy, improved skin moisturization, helped prevent sun-provoked facial redness, did not worsen rosacea, and was easily incorporated into their skincare regimen. Half would switch to the product, and 80% of subjects would buy and recommend the product. CONCLUSION: The product was well tolerated in rosacea-prone subjects, producing objective and subjective improvements in skin status and symptoms.
format Online
Article
Text
id pubmed-5476437
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-54764372017-06-26 Evaluation of a novel very high sun-protection-factor moisturizer in adults with rosacea-prone sensitive skin Grivet-Seyve, Mathieu Santoro, Francine Lachmann, Nadège Clin Cosmet Investig Dermatol Original Research BACKGROUND/OBJECTIVE: Rosacea-prone sensitive skin requires high sun-protection factor (SPF) moisturizers. This study evaluated Daylong Extreme SPF 50+ lotion, a novel cream containing five ultraviolet filters, two emollients, and three skin conditioners. SUBJECTS AND METHODS: This was an open-label, single-center study. On day 1, before treatment, subjects answered a questionnaire on their skin conditions and sunscreen habits, and both subjects and dermatologist evaluated skin status. Subjects applied the product once daily in the morning to the face for 21 days, and after approximately 3–5 minutes they assessed tolerability and short-term cosmetic acceptability in a questionnaire and daily diary. On day 22, the dermatologist and subjects evaluated skin status for long-term tolerance and cosmetic acceptability. RESULTS: The study enrolled 44 individuals (mean age 58.8 years, 91% female). At baseline, most subjects (39 of 44) showed erythema, and ~30% showed dryness and scaling. Dermatologists noted four cases of pustules and one case of papules. After 21 days’ treatment with the product, the dermatologist reported significantly less erythema, dryness and scaling, three cases of pustules and two cases of papules. At baseline, ~75% of subjects noted a feeling of dryness, >50% reported tension, and nearly 25% reported tickling. After using the product for 21 days, subjects reported significantly less tension, dryness, and tickling. Some subjects noted itching and burning before and after using the product. One subject noted papules during treatment. Most subjects said that the product was pleasant, did not irritate the skin or cause stinging/burning, was easy to apply, quickly absorbed, and nongreasy, improved skin moisturization, helped prevent sun-provoked facial redness, did not worsen rosacea, and was easily incorporated into their skincare regimen. Half would switch to the product, and 80% of subjects would buy and recommend the product. CONCLUSION: The product was well tolerated in rosacea-prone subjects, producing objective and subjective improvements in skin status and symptoms. Dove Medical Press 2017-06-10 /pmc/articles/PMC5476437/ /pubmed/28652793 http://dx.doi.org/10.2147/CCID.S134857 Text en © 2017 Grivet-Seyve et al. This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/. The license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Original Research
Grivet-Seyve, Mathieu
Santoro, Francine
Lachmann, Nadège
Evaluation of a novel very high sun-protection-factor moisturizer in adults with rosacea-prone sensitive skin
title Evaluation of a novel very high sun-protection-factor moisturizer in adults with rosacea-prone sensitive skin
title_full Evaluation of a novel very high sun-protection-factor moisturizer in adults with rosacea-prone sensitive skin
title_fullStr Evaluation of a novel very high sun-protection-factor moisturizer in adults with rosacea-prone sensitive skin
title_full_unstemmed Evaluation of a novel very high sun-protection-factor moisturizer in adults with rosacea-prone sensitive skin
title_short Evaluation of a novel very high sun-protection-factor moisturizer in adults with rosacea-prone sensitive skin
title_sort evaluation of a novel very high sun-protection-factor moisturizer in adults with rosacea-prone sensitive skin
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476437/
https://www.ncbi.nlm.nih.gov/pubmed/28652793
http://dx.doi.org/10.2147/CCID.S134857
work_keys_str_mv AT grivetseyvemathieu evaluationofanovelveryhighsunprotectionfactormoisturizerinadultswithrosaceapronesensitiveskin
AT santorofrancine evaluationofanovelveryhighsunprotectionfactormoisturizerinadultswithrosaceapronesensitiveskin
AT lachmannnadege evaluationofanovelveryhighsunprotectionfactormoisturizerinadultswithrosaceapronesensitiveskin